News

Blueprint Medicines gets more ducks in a row before CEO transition; Paul Stoffels has his work cut out for him at Gilead’s crumbling partner

Philina Lee → When Jeff Albers announced he would no longer be CEO of Blueprint Medicines, the leadership carousel at the Aykakit maker had yet to wind down. Yes, Kate Haviland is next in line […]

No Picture
News

Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on studies evaluating the combination of magrolimab plus azacitidine due to […]

No Picture
News

Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments

SAN FRANCISCO: SAN FRANCISCO, Jan. 25, 2022 /PRNewswire/ — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer. Additional […]